-transparent.png){kind=logo}
Malignancies of thymus-derived (T) lymphocytes can be divided into two major groups: diseases of T cells expressing immature T cell markers (T-ALL, T cell lymphoblastic lymphoma) and diseases of malignant T cells expressing markers in a pattern similar to normal mature T cells (T cell CLL, ATL, various forms of CTCL, and T-PLL). Until specific pathways of normal cell maturation are known, the relationship of phenotypic expression of various T cell markers by malignant T cells to a particular stage of normal T cell differentiation must remain speculative. However, phenotypic characterization of malignant T cells is an important first step in the study of events that transpire in the development of T cell malignancies. Future parallel study into the mechanisms of normal and aberrant T cell maturation will undoubtedly lead to greater understanding of the pathogenesis of the T cell malignancies, and therefore pave the way for specific therapies for these difficult-to-treat syndromes.
E A Harden, and
B F Haynes
April 1986,
[Rinsho ketsueki] The Japanese journal of clinical hematology,
E A Harden, and
B F Haynes
January 2011,
Methods in molecular biology (Clifton, N.J.),
E A Harden, and
B F Haynes
December 1988,
Journal of immunology (Baltimore, Md. : 1950),
E A Harden, and
B F Haynes
May 1988,
The Journal of clinical investigation,
E A Harden, and
B F Haynes
April 2006,
Immunology,
E A Harden, and
B F Haynes
January 2015,
Tsitologiia,
E A Harden, and
B F Haynes
January 1989,
European journal of haematology. Supplementum,
E A Harden, and
B F Haynes
March 2008,
Journal of immunology (Baltimore, Md. : 1950),
E A Harden, and
B F Haynes
April 2007,
European journal of immunology,
E A Harden, and
B F Haynes
January 1999,
Hematology (Amsterdam, Netherlands),
